Scilex Holding Company
$7.54
+1.8%Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -0.2).
Valuation inputs: P/E -0.2, earnings yield N/A, momentum +1.8%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE +1.7%, ROIC +10.3%).
Profitability stack: net margin -11.9%, ROE +1.7%, ROIC +10.3%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets +158.0%, momentum +1.8%, net margin -11.9%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Scilex Holding Company Market vs Earnings Trajectory
Loading price and EPS data...
Scilex Holding Company Fair Value Envelope
Scilex Holding Company Profit Bridge
Profitability Analysis
Gross Margin
Strong gross margins indicate healthy pricing and efficient production or service delivery.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Scilex Holding Company Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Scilex Holding Company Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.
Working Capital
Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.
Asset Composition
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
Scilex Holding Company Street Expectations Map
No Target Data
No analyst price targets available for sclx.
Scilex Holding Company Insider Positioning
During the last 12 months, insiders have purchased $8.90M and sold $13.55M worth of SCLX shares, resulting in $4.65M of net selling activity.
3 Months
3.9M
4.68M
650.0K
780.00K
+3.9M
+$3.90M
3-6 Months
0
0.00
20.7M
12.77M
-12.8M
-$12.77M
6-9 Months
240.0K
4.22M
0
0.00
+4.2M
+$4.22M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Ji Henry
Director, Officer: Exec Chair, Ceo And President
$6.01M
Ma Stephen Hoi
Director, Officer: Cfo, Coo And Secretary
$1.83M
Chun Jay
Director
$352K
Followwill Dorman
Director
$352K
Wu Yue Alexander
Director
$352K
Top Sellers
Scilex Holding Co
10 Percent Owner
$12.77M
Ji Henry
Director, Officer: Exec Chair, Ceo And President
$780K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $4.65M net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider buyers vs. 2 sellers. Broad-based buying across management team suggests widespread confidence.
sclx Dividend History
Learning Layer
Related Guides
Build conviction on SCLX by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.